Spruce Biosciences Inc Dossier - Source-backed chat

Spruce Biosciences Inc

SPRBNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.55

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $44.77Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $128.7M

Enterprise Value $39.5M

Shares Outstanding 2.9M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Spruce Biosciences has executed a highly strategic pivot, shifting its primary focus away from tildacerfont in congenital adrenal hyperplasia (CAH) to prioritize tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB). This transition significantly reduces cash burn, as evidenced by a narrowed net loss and reduced R&D expenses. Backed by positive FDA Type B meetings confirming that existing integrated clinical and natural history data can support an accelerated approval pathway, Spruce is on track to submit a BLA in Q4 2026. With a strengthened balance sheet following an April 2026 public offering and a $50 million growth-capital facility extending its runway into the second half of 2027, Spruce is well-positioned to transition into a commercial-stage rare disease company.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$120.00

Mean target$151.00

High · most bullish analyst$230.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case assumes the FDA requests additional clinical data or raises manufacturing readiness concerns, delaying the BLA submission or approval timeline beyond 2027. High cash burn associated with commercial launch preparation and the confirmatory trial exhausts existing capital sooner than expected, forcing dilutive equity raises. Furthermore, the TAMARIND Phase 2 trial fails to show efficacy, rendering the tildacerfont asset obsolete.

Base CaseCentral scenario

The base case assumes Spruce successfully submits the BLA for TA-ERT in Q4 2026. The FDA grants priority review, leading to accelerated approval by mid-2027. The company leverages its newly expanded commercial leadership team to launch TA-ERT in the U.S., targeting an estimated addressable patient pool of 450 in the U.S. and benchmarking pricing around $2.0 million per year. The company also secures and monetizes a Rare Pediatric Disease Priority Review Voucher (PRV), further strengthening its financial position.

Bull CaseUpside scenario

The bull case for Spruce Biosciences centers on the successful regulatory approval and commercialization of TA-ERT for Sanfilippo Syndrome Type B (MPS IIIB), supported by robust long-term clinical data showing stabilization of cognitive function. A successful BLA submission in Q4 2026 could lead to FDA approval, commercial launch, and potential monetization of a Priority Review Voucher valued at approximately $150 million. Additionally, positive Phase 2/3 data for tildacerfont in CAH in late 2026 would provide a secondary high-value clinical asset.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Clear regulatory path to accelerated approval for TA-ERT based on surrogate biomarker (heparan sulfate) normalization.
Substantial market opportunity in MPS IIIB with no currently approved disease-modifying therapies.
Strong financial runway extending into H2 2027, supported by $107.3 million in preliminary cash (as of April 30, 2026) and a $50 million debt facility.
Potential non-dilutive funding from the monetization of a Rare Pediatric Disease Priority Review Voucher (PRV) upon approval.

Key Investment Risks

Clinical and regulatory risks associated with the FDA's final review of the integrated clinical and natural history data.
Execution risk in initiating and completing the required confirmatory randomized controlled trial.
Commercialization risks in identifying, accessing, and retaining patients in an ultra-rare disease market.

Thesis Invalidation Triggers

FDA refusal to file or complete review of the TA-ERT BLA.
Inability to initiate the confirmatory trial prior to potential accelerated approval.
Severe clinical safety signals emerging from the ongoing TA-ERT clinical program or expanded access programs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.